Third approved indication for SKYRIZI® (risankizumab) and the first specific IL-23 inhibitor for the treatment of Crohn’s disease in the European Union (EU) A significantly higher proportion of patients on SKYRIZI achieved clinical… Read More
VANCOUVER, BC — Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the publication of an abstract highlighting new clinical data for zanidatamab, a HER2-targeted bispecific… Read More
TORONTO, ON — Takeda Canada Inc. (“Takeda”) is pleased to announce that TAKHZYRO® (lanadelumab), the first approved monoclonal antibody for the treatment of Hereditary Angioedema (HAE) has been named the 2022… Read More
VANCOUVER, BC — InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today announced the… Read More
VANCOUVER, BC — NervGen Pharma Corp. (TSX-V: NGEN; OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system… Read More
